CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.
Presenters highlighted notable recent research involving drugs to address diabetes and cardiometabolic health, including DECLARE-TIMI 58, REWIND, GLP-1 receptor agonist and SGLT2 inhibitor meta-analyses and DAPA-HF.
DECLARE-TIMI 58 trial
Beyond improved cardiovascular outcomes, the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) may also offer adults with type 2 diabetes the potential to prevent and treat kidney disease, according to findings published in The Lancet
Source link
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life and that is to make people understand that the conventional method of treating T2DM is not beneficial. Type 2 diabetes is reversible and the best way to reverse T2DM is through diet and lifestyle modifications. He now decided to help people with type 2 diabetes by offering online coaching to reverse their diabetes.
